Thank you, welcome to Akebia Therapeutics, Inc.'s fourth quarter and full year 2025 financial results and business updates conference call. Please note that a press release was issued earlier today, ...

Thank you, Jason. After that, we'll provide updates on the significant progress we've made with lonvo-z, which is being developed as a potential one-time treatment for patients with hereditary ...